PET/CT helps predict survival of patients with prostate cancer

06/26/2013 | MolecularImaging.net

Metabolic imaging using 18F-FDG-PET/CT helps predict the overall survival of patients with castrate-resistant metastatic prostate cancer, according to a study published in The Journal of Nuclear Medicine. Data provided by the imaging method "may be useful in assessing the comparative effectiveness of various conventional and emerging treatment strategies," researchers said.

View Full Article in:

MolecularImaging.net

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI